


PromptDegrader™ Platform

*Mastering the Unstructured:
Rationally Degrading IDR Proteins*



28 October 2025



RDP's Vision

The Challenge

Many serious diseases — cancer, autoimmune, and neurodegenerative — are driven by proteins with **intrinsically disordered regions (IDRs)**.

IDRs lack stable, puzzle-piece-like structures and instead constantly shift shape to support different cellular functions — much like chameleons. This made them **historically “undruggable”** and resistant to traditional drug discovery.



Our Breakthrough

PromptDegrader™: proprietary platform for a **rational design** of small molecules, to degrade disease-relevant IDRs.

Employs a **ML-driven** modeling approach to identify unconventional IDR states suitable for **docking**, followed by *in silico* screening and *in vitro* validation tools.



The Impact

Enables multi-ligase recruitment for robust degradation via **multiple pathways**.


Opens entirely new therapeutic avenues for conditions once considered untreatable.

Pioneering the **IDR targeted protein degradation (TPD)** revolution in oncology and beyond.



Innovative Targeted Protein Degradation of IDRs

Beyond PROTACs and Molecular Glues



Targeted protein degradation by PROTACs

A PROTAC simultaneously binds a Target of Interest (TOI) and requires an E3 ubiquitin ligase complex, leading to ubiquitination and degradation of the TOI via the ubiquitin-proteasome system.


Targeted protein degradation by PromptDegrader™

The PromptDegrader™ has a **monovalent** MoA that binds to an **Intrinsically Disordered Region (IDR)** of the TOI and induces its degradation.

PromptDegrader™: Small molecules with a clear regulatory path complying to Lipinski's rules, no Hook Effect, no competitive binding of PROTAC metabolites, improved PK / PD compared to PROTACs, orally available.

PromptDegrader™: Multi-Modal Targeted Protein Degradation

- ❖ IDR proteins are considered hard to drug*
- ❖ PromptDegraders can degrade IDR proteins
- ❖ Not only reliant on E3 modulation of one ligase, like PROTACs and Molecular Glues
- ❖ Avoids inherent and acquired resistance
- ❖ Vastly greater chemical space for ligands



*A.C. Pan. et al. "Molecular Basis of Small-Molecule Binding to α -Synuclein",


"Drugging IDPs, however, has proven difficult due to their highly conformationally dynamic nature and the challenges associated with experimentally characterizing their conformational ensembles at atomic resolution. Because IDPs generally cannot be meaningfully represented by a single dominant conformation, or even a small number of substantially populated conformations, they are generally not suitable targets for conventional structure-based drug design methods, in which small molecules are designed to optimize interactions with a particular binding pocket in a folded protein. "

J. Am. Chem. Soc. 2022, 144, 2501–2510. <https://doi.org/10.1021/jacs.1c07591>


Benefits over PROTACs and Glues

PromptDegrader™ TPD Comparison	PromptDegrader™	Molecular Glues (IMiDs)	PROTACs
Targets IDRs of proteins	●	●	●
Freedom to operate / no IP “minefield”	●	●	●
Rational design			
I. Activity screening	●	●	●
II. Biopharmaceutical & chemical optimization			
Safety: no hook effect, reduced metabolization	●	●	●
Multi-modal: not reliant on single E3 ligase for degradation; less risk of acquired and inherent resistance	●	●	●
Potency in cells	High nM <i>in vitro</i>	Low nM <i>in vitro</i>	Low nM <i>in vitro</i>
<i>In vivo</i> potency	1–40 mg/kg, low μM <i>ex vivo</i>	1–50 mg/kg, nM <i>ex vivo</i>	1–50 mg/kg, nM <i>ex vivo</i>
Potency in humans	TBD	20–200 mg/kg/day*	30–1000 mg/kg/day*

Extending the PromptDegrader™ Platform




PromptDegrader™ Discovery Process *via* Rational Design



- ❖ New small molecule pharmacophores, not reliant on *cereblon*, FTO
- ❖ Rational design based on *in silico* model
- ❖ Designed for proteins with IDRs (applicable for ordered proteins as well)

Uniquely Targeting IDRs of Proteins

In Silico Process from IDR Protein to Rationally Designed Small Molecule Degradere



c-Myc Degradator Program Overview (1 of 2)

Compounds with drug-like properties identified within 6 months of project start

- Development activities in progress, in Lead Optimization phase

Proof of activity established with *in vitro*, *in vivo* and *ex vivo* patient cells

- Xenograft models (A549 lung cancer, MDA-MB-231 breast cancer)
- RDP's results have been externally validated by leading Myc-KOLs
- *Ex vivo* patient data in multiple myeloma cells

Mechanism of Action (MoA)

- Autophagy, lysosomal, and proteasomal degradation with multiple ligases involved
- Direct target engagement of PromptDegradators showed by SEC, NMR, HDX, and CETSA
- Global translational inhibition does not play a role, 30 most regulated proteins identified

New chemical entity (NCE) degrader series & Specificity

- > 5 pharmacophores identified
- Our compounds are highly specific, our c-Myc degrader does not degrade N-Myc (or any of our other pipeline targets)

c-Myc Degradation Program Overview (2 of 2)

● **Small molecule hits more active than literature compounds**, e.g., MYCi975 (EC_{50} 7.5 μ M) and after 6 months comparable activity compared to WBC100 (EC_{50} 7.5 μ M, DC_{50} 6.98 μ M)

● **PromptDegradation™** *in silico* model of IDR proteins, in parallel set up of wet lab assays; docking cavity according to proprietary know-how

● **c-Myc degradation** in Western Blot and parallel Flow Cytometry as well as Luciferase assay; hits D_{max} > 90 %, EC_{50} high nM to 2.7 μ M

● **Off-target liabilities** are addressed through iterative SAR-driven refinement, utilizing our AI *in silico* model in lead optimization

● **No toxicity** in C57BL/6 mice at 60 mg/kg and 20–30 mg/kg in nude mice after 14x daily oral dose

● **SAR** of different pharmacophores ongoing to strengthen the *in silico* model

● **Thermal shift (CETSA) assay** of lead compounds (02004, 09024) suggests a direct binding effect and limited off-target effects in > 7,000 proteins

RDP Pharma Overview and Leadership



Peter Hertig – Chairman of the Board

Over 50 years in global leadership and investment across private equity, real estate, automotive, and pharma, with board and M&A experience.



Susanne Oelrich – CEO

30+ years in CRO senior management, covering clinical operations, global processes, project, and data management.



Dr. Christian Kuehne – CSO

30+ years of scientific innovation across modalities, and a pioneer in targeting intrinsically disordered regions to drug challenging targets.



Dr. Michael Ahrweiler – CDO

Accomplished scientist and strategist with 30+ years in development and deal-making across all phases.

Company Overview

- ❖ Established: 2019
- ❖ Legal Status: Privately held Swiss corporation
- ❖ Headquarters: Romanshorn, Switzerland

Location & Units

- ❖ Romanshorn, Switzerland: Administration & Computational Science
- ❖ Vienna, Austria: Wet Lab Facilities with Biology & Chemistry

Team

- ❖ Employees / FTEs: > 30

PromptDegrader™ Research Team



Dr. Markus Muellner

CTO

About Markus

15 years of biotech leadership in scientific innovation and business creation across multiple modalities and targeted protein degradation.

Team Members



Dr. Florian Kellner

Head of the
Biology Unit

Team:
10 Scientists



Dr. Antony Crisp

Head of the
Chemistry Unit

Team:
5 Scientists







Dr. Paulina Pacak

Head of the Computational
Science Unit

Team:
3 Scientists

PromptDegrader™ Pipeline

Target	Indications	Hit Identification	Hit-to-Lead/ Lead Generation	Lead Optimization	IND-Enabling Studies
E7	Head & Neck, Cervical Cancer				
c-Myc	Multiple Cancers				
CTNNB1	Multiple Cancers				
Undisclosed (Co-development with EDDC)	Anti-Inflammatory				

CONTACT



Michael Ahrweiler
Founder, CDO

info@rdp-pharma.com
Amriswilerstrasse 51
CH-8590 Romanshorn
Switzerland
+41 71 466 33 68
www.rdp-pharma.com